Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Arrhythmias

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 61 articles: HTML format

Single Articles

July 2024
1. SIMON TG, Singer DE, Zhang Y, Mastrorilli JM, et al
   Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
   Ann Intern Med. 2024 Jul 9. doi: 10.7326/M23-3067.
   PubMed     Abstract available
   
   
   
2. BARNES GD
   In device-detected AF, DOACs vs. aspirin or placebo reduce ischemic stroke and increase major bleeding.
   Ann Intern Med. 2024 Jul 2. doi: 10.7326/ANNALS-24-00652.
   PubMed     Abstract available
   
   
   June 2024
3. WEITZ HH, Merli GJ, Lip GYH
   Annals Consult Guys - The ABCs of Atrial Fibrillation.
   Ann Intern Med. 2024;177:e2400618CG.
   PubMed    
   
   
   
4. FIELD TS
   In cryptogenic stroke and atrial cardiopathy, apixaban did not reduce recurrent stroke vs. aspirin.
   Ann Intern Med. 2024;177:JC65.
   PubMed     Abstract available
   
   
   May 2024
5. SPOSATO LA, Hill MD
   In AF, CHA(2)DS(2)-VASc 1 subgroups did not differ for predicting risk for arterial thromboembolism at 1 y.
   Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0023.
   PubMed     Abstract available
   
   
   
6. DUNN A
   In older patients with AF and frailty, switching from VKA to NOAC therapy increased a composite of major or CRNM bleeding at 12 mo.
   Ann Intern Med. 2024;177:JC57.
   PubMed     Abstract available
   
   
   March 2024
7. SHADRIN IY, Newby LK
   In subclinical AF, apixaban reduced stroke or systemic embolism but increased major bleeding vs. aspirin at 3.5 y.
   Ann Intern Med. 2024;177:JC26.
   PubMed     Abstract available
   
   
   January 2024
8. ISHIGUCHI H, Lip GYH
   In symptomatic AF, catheter ablation vs. medical therapy reduced depression and anxiety symptoms at 12 mo.
   Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0105.
   PubMed     Abstract available
   
   
   
9. LOPEZ J, Borzak S
   In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or myocardial injury after noncardiac surgery at 14 d.
   Ann Intern Med. 2024;177:JC3.
   PubMed     Abstract available
   
   
   December 2023
10. BROPHY J
    In symptomatic AF with end-stage HF, adding catheter ablation to medical therapy improved clinical outcomes at 18 mo.
    Ann Intern Med. 2023;176:JC137.
    PubMed     Abstract available
    
    
    October 2023
11. MCINTYRE WF, Vadakken ME, Connolly SJ, Mendoza PA, et al
    Atrial Fibrillation Recurrence in Patients With Transient New-Onset Atrial Fibrillation Detected During Hospitalization for Noncardiac Surgery or Medical Illness : A Matched Cohort Study.
    Ann Intern Med. 2023 Oct 3. doi: 10.7326/M23-1411.
    PubMed     Abstract available
    
    
    
12. BARNES GD
    In adults, MRAs reduce AF occurrence vs. non-MRAs.
    Ann Intern Med. 2023;176:JC114.
    PubMed     Abstract available
    
    
    September 2023
13. TON IT, Moon J, Sengul A, Mody FV, et al
    Evidence-Based Cardiovascular Disease Medicines' Availability in Low-Cost Generic Drug Programs in the United States : A Cross-Sectional Study.
    Ann Intern Med. 2023 Sep 5. doi: 10.7326/M23-0287.
    PubMed     Abstract available
    
    
    August 2023
14. 
    Correction: Atrial Fibrillation.
    Ann Intern Med. 2023 Aug 15. doi: 10.7326/L23-0291.
    PubMed    
    
    
    
15. CARLIN S, Douketis J
    In AF, the effects of DOACs vs. warfarin on death and stroke/systemic embolism vary by baseline CrCl level.
    Ann Intern Med. 2023 Aug 1. doi: 10.7326/J23-0054.
    PubMed     Abstract available
    
    
    July 2023
16. 
    Correction: Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Ann Intern Med. 2023 Jul 25. doi: 10.7326/L23-0266.
    PubMed    
    
    
    
17. AL-KHATIB SM
    Atrial Fibrillation.
    Ann Intern Med. 2023;176:ITC97-ITC112.
    PubMed     Abstract available
    
    
    June 2023
18. ALBERTS MJ
    After ICH, starting long-term therapeutic oral anticoagulation in patients with AF reduces MACE at 1 to 3 y.
    Ann Intern Med. 2023;176:JC71.
    PubMed     Abstract available
    
    
    May 2023
19. RAY WA, Chung CP, Stein CM, Smalley W, et al
    Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
    Ann Intern Med. 2023 May 23. doi: 10.7326/M22-3238.
    PubMed     Abstract available
    
    
    
20. JOUNG B, Kim D, Yang PS, Sung JH, et al
    Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients.
    Ann Intern Med. 2023;176:eL220502.
    PubMed    
    
    
    
21. QIU M, Du L
    Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients.
    Ann Intern Med. 2023;176:eL220501.
    PubMed    
    
    
    March 2023
22. CHEW DS, Piccini JP
    Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation.
    Ann Intern Med. 2023;176:eL220517.
    PubMed    
    
    
    
23. ANDERSON CE, Lieberman RA, Olshansky B
    Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation.
    Ann Intern Med. 2023;176:eL220516.
    PubMed    
    
    
    
24. TAN NS
    In symptomatic AF, cryoballoon ablation reduced progression to persistent AF vs. antiarrhythmic therapy at 3 y.
    Ann Intern Med. 2023;176:JC29.
    PubMed     Abstract available
    
    
    
25. DUNN A
    In AF, underdosing of DOACs was not linked to reduced bleeding.
    Ann Intern Med. 2023;176:JC32.
    PubMed     Abstract available
    
    
    
26. RA J, Oberdier MT, Suzuki M, Vaidya D, et al
    Implantable Defibrillator System Shock Function, Mortality, and Cause of Death After Magnetic Resonance Imaging.
    Ann Intern Med. 2023;176:289-297.
    PubMed     Abstract available
    
    
    January 2023
27. CENTOR RM, Doppalapudi H
    Annals On Call - Atrial Fibrillation: Control Rate or Rhythm?
    Ann Intern Med. 2023 Jan 3:eA220001. doi: 10.7326/A22-0001.
    PubMed    
    
    
    
28. LADER EW
    In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y.
    Ann Intern Med. 2023;176:JC2.
    PubMed     Abstract available
    
    
    
29. GULATI S, Eckman MH
    Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Ann Intern Med. 2023;176:1-9.
    PubMed     Abstract available
    
    
    December 2022
30. MAHESHWARI A, Norby FL, Inciardi RM, Wang W, et al
    Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study.
    Ann Intern Med. 2022 Dec 20. doi: 10.7326/M22-1638.
    PubMed     Abstract available
    
    
    
31. KO D, Benjamin EJ
    Atrial Cardiopathy and Cardioembolic Stroke.
    Ann Intern Med. 2022 Dec 20. doi: 10.7326/M22-3476.
    PubMed    
    
    
    
32. 
    Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/L22-0482.
    PubMed    
    
    
    
33. WEITZ HH, Merli GJ, Siontis K
    Web Exclusive. Annals Consult Guys - Postoperative Atrial Fibrillation.
    Ann Intern Med. 2022;175:CG1.
    PubMed    
    
    
    November 2022
34. HEALEY JS, Krahn AD, Bashir J, Amit G, et al
    Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial.
    Ann Intern Med. 2022 Nov 8. doi: 10.7326/M22-1566.
    PubMed     Abstract available
    
    
    
35. LAU WCY, Torre CO, Man KKC, Stewart HM, et al
    Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
    Ann Intern Med. 2022 Nov 1. doi: 10.7326/M22-0511.
    PubMed     Abstract available
    
    
    
36. 
    Correction: Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban and Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2022;175:1627-1628.
    PubMed    
    
    
    October 2022
37. DAWWAS GK, Cuker A, Barnes GD, Lewis JD, et al
    Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study.
    Ann Intern Med. 2022 Oct 18. doi: 10.7326/M22-0318.
    PubMed     Abstract available
    
    
    September 2022
38. KIM D, Yang PS, You SC, Jang E, et al
    Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients : A Nationwide Propensity Score-Weighted Study.
    Ann Intern Med. 2022 Sep 6. doi: 10.7326/M21-4798.
    PubMed     Abstract available
    
    
    August 2022
39. CHEW DS, Zhou K, Pokorney SD, Matchar DB, et al
    Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/M21-4653.
    PubMed     Abstract available
    
    
    
40. KANTHARIA BK
    Left Atrial Appendage Occlusion Versus Anticoagulation in Atrial Fibrillation: Equipoise When Bleeding Risk Is High.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/M22-2271.
    PubMed    
    
    
    
41. 
    Summary for Patients: Occlusion Devices Versus Blood Thinners for Atrial Fibrillation.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/P22-0015.
    PubMed    
    
    
    July 2022
42. SIONTIS KC, Gersh BJ, Weston SA, Jiang R, et al
    Associations of Atrial Fibrillation After Noncardiac Surgery With Stroke, Subsequent Arrhythmia, and Death : A Cohort Study.
    Ann Intern Med. 2022 Jul 26. doi: 10.7326/M22-0434.
    PubMed     Abstract available
    
    
    
43. ALMHRI A, Leong DP
    In AF, CV benefits of catheter ablation vs. medical therapy may vary by age.
    Ann Intern Med. 2022;175:JC77.
    PubMed     Abstract available
    
    
    June 2022
44. CHOI SE, Lip GYH
    USPSTF found insufficient evidence on the benefits and harms of screening adults >/=50 y for AF.
    Ann Intern Med. 2022;175:JC62.
    PubMed     Abstract available
    
    
    February 2022
45. HUANG HK, Liu PP, Lin SM, Hsu JY, et al
    Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants : A Nationwide Analysis.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-3498.
    PubMed     Abstract available
    
    
    
46. COLIVICCHI F
    In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding.
    Ann Intern Med. 2022;175:JC22.
    PubMed     Abstract available
    
    
    
47. SANTULLI G, Mone P
    In permanent AF with narrow QRS, AV junction ablation + CRT vs. rate-control drug therapy reduced mortality.
    Ann Intern Med. 2022;175:JC21.
    PubMed     Abstract available
    
    
    January 2022
48. YOUSUFUDDIN M, Jahangir A
    In older patients at high risk for stroke, intensive AF screening with an implantable loop recorder did not reduce stroke.
    Ann Intern Med. 2022;175:JC8.
    PubMed     Abstract available
    
    
    
49. YOUSUFUDDIN M, Jahangir A
    In adults aged 75 to 76 y, systematic AF screening reduced morbidity and mortality at 6 y.
    Ann Intern Med. 2022;175:JC9.
    PubMed     Abstract available
    
    
    December 2021
50. WILLETT LR, Kim S
    In paroxysmal AF, first-line catheter ablation vs. antiarrhythmic drugs reduces atrial arrhythmia recurrence.
    Ann Intern Med. 2021 Dec 7. doi: 10.7326/ACPJ202112210.
    PubMed     Abstract available
    
    
    October 2021
51. SHAH S, Garg J
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1489-1490.
    PubMed    
    
    
    
52. DAWWAS GK, Barnes GD, Cuker A, Lewis JD, et al
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1490.
    PubMed    
    
    
    
53. RODWIN BA
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1488-1489.
    PubMed    
    
    
    
54. MANSI IA, Bhushan S, Albracht DE
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1489.
    PubMed    
    
    
    September 2021
55. SAMPSON C
    In acute atrial flutter, adding pharmacologic before electrical cardioversion did not increase conversion to normal sinus rhythm.
    Ann Intern Med. 2021 Sep 7. doi: 10.7326/ACPJ202109210.
    PubMed     Abstract available
    
    
    August 2021
56. PIANO MR, Hwang CL
    Holiday Heart Confirmed: Alcohol-Associated Atrial Fibrillation.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-3193.
    PubMed    
    
    
    
57. 
    Summary for Patients: Alcohol Drinking and Atrial Fibrillation.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/P21-0008.
    PubMed    
    
    
    
58. MARCUS GM, Vittinghoff E, Whitman IR, Joyce S, et al
    Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-0228.
    PubMed     Abstract available
    
    
    July 2021
59. KIM DH, Pawar A, Gagne JJ, Bessette LG, et al
    Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
    Ann Intern Med. 2021 Jul 20. doi: 10.7326/M20-7141.
    PubMed     Abstract available
    
    
    June 2021
60. KARIMZAD K, Deswal A
    In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo.
    Ann Intern Med. 2021;174:JC69.
    PubMed     Abstract available
    
    
    April 2021
61. GUE YX, Lip GYH
    In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.
    Ann Intern Med. 2021;174:JC43.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.